Modality
ASO
MOA
CDK2i
Target
JAK2
Pathway
Angiogenesis
PsoriasisADPKDGBM
Development Pipeline
Preclinical
~Feb 2013
→ ~May 2014
Phase 1
~Aug 2014
→ ~Nov 2015
Phase 2
~Feb 2016
→ ~May 2017
Phase 3
~Aug 2017
→ ~Nov 2018
NDA/BLA
~Feb 2019
→ ~May 2020
Approved
Aug 2020
→ Mar 2030
ApprovedCurrent
NCT07782320
1,263 pts·Psoriasis
2020-08→2030-03·Completed
1,263 total pts1 indication
CompletedCurrentUpcoming
Catalysts (1)
2030-03-123.9y awayPh3 Readout· Psoriasis
Trial Timeline
Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2
Approved
Complet…
Catalysts
Ph3 Readout
2030-03-12 · 3.9y away
Psoriasis
Completed|StartCompletionToday
Trials (1)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT07782320 | Approved | Psoriasis | Completed | 1263 | Biomarker |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| PFE-3703 | Pfizer | Phase 1/2 | CDK2 | |
| Tirafotisoran | Roche | Phase 2 | CD38 | |
| ABB-3951 | AbbVie | Phase 2/3 | TNFα | |
| AZN-6870 | AstraZeneca | Phase 2/3 | EGFR | |
| Tirasotorasib | Takeda | NDA/BLA | IL-17A | |
| Mavuglumide | Bayer | Approved | GLP-1R | |
| DSN-3066 | Daiichi Sankyo | Phase 3 | IL-13 | |
| GIL-9227 | Gilead Sciences | Phase 2/3 | GPRC5D | |
| REG-2328 | Regeneron | Phase 1 | BCMA | |
| MRN-7409 | Moderna | NDA/BLA | SHP2 |